A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Autores de IIS La Fe

• Juan Sandoval Del Amor

  Autor

• Luis Montuenga Badía

  Autor

• Manuel Esteller Badosa

  Autor

Participantes ajenos a IIS La Fe

• Mendez-Gonzalez J
• Nadal E
• Chen G
• Carmona FJ
• Sayols S
• Moran S
• Heyn H
• Vizoso M
• Gomez A
• Sanchez-Cespedes M
• Assenov Y
• Müller F
• Bock C
• Taron M
• Mora J
• Muscarella LA
• Liloglou T
• Davies M
• Pollan M
• Pajares MJ
• Torre W
• Brambilla E
• Field JK
• Roz L
• Lo Iacono M
• Scagliotti GV
• Rosell R
• Beer DG

Abstract

Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard.